Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEAYA BiosciencesIDYA +0.37%53 3-Year Book Growth Rate is 17.10% as of Jun. 2026, which is 15% above its 10-year median of 14.90. GuruFocus rates IDYA with a GF Score™ of 53/100 and a GF Value™ of $201.38 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,126 Biotechnology companies, IDEAYA Biosciences ranks better than 82.59% on this metric.
During the past 12 months, IDEAYA Biosciences's average Book Value per Share Growth Rate was 13.60% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 17.10% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 13.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 9 years, the highest 3-Year average Book Value per Share Growth Rate of IDEAYA Biosciences was 17.10% per year. The lowest was 12.50% per year. And the median was 14.90% per year.
IDEAYA Biosciences (NAS:IDYA) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
IDEAYA Biosciences 3-Year Book Growth Rate Related Terms
IDYA vs LEGN, DNLI, TNGX: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, IDEAYA Biosciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEAYA Biosciences 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where IDEAYA Biosciences's 3-Year Book Growth Rate falls into.
IDEAYA Biosciences 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 17.10% mean?
IDEAYA Biosciences (IDYA) has a 3-Year Book Growth Rate of 17.10% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for IDEAYA Biosciences and its competitors. This is 15% above median its historical median of 14.90. Over the past decade, IDEAYA Biosciences' 3-Year Book Growth Rate has ranged from 12.50 to 17.10. According to the industry distribution chart, IDEAYA Biosciences ranks #196 out of 1126 companies in the Biotechnology industry, placing it in the top 17.4%.
Is IDEAYA Biosciences' 3-Year Book Growth Rate too high?
IDEAYA Biosciences' current 3-Year Book Growth Rate of 17.10% is 15% above median its 10-year median of 14.90. Over the past 10 years, this metric has ranged from a low of 12.50 to a high of 17.10. Based on the distribution chart, IDEAYA Biosciences ranks #196 out of 1126 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, IDEAYA Biosciences has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' 3-Year Book Growth Rate compare to LEGN and DNLI?
According to the Biotechnology industry distribution chart, IDEAYA Biosciences ranks #196 out of 1126 companies for 3-Year Book Growth Rate. This places IDEAYA Biosciences in the top 17% of its industry — outperforming the majority of peers. Historically, IDEAYA Biosciences' own 3-Year Book Growth Rate has ranged from 12.50 to 17.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for IDEAYA Biosciences and its competitors. IDEAYA Biosciences's current 3-Year Book Growth Rate is 17.10%, which is 15% above median its own 10-year median of 14.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $201.38, compared to a current price of $37.58 — trading 81.3% below its estimated fair value. The current 3-Year Book Growth Rate is 17.10%, which is 15% above median its 10-year median of 14.90. IDEAYA Biosciences' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current 3-Year Book Growth Rate is 17.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEAYA Biosciences (IDYA) Overvalued in 2026?
Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued.
The current stock price of $37.58 is trading 81.3% below its estimated GF Value™ of $201.38.
GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.
Key valuation signals for IDYA:
3-Year Book Growth Rate: 17.10% (15% above median its 10-year median of 14.90)
GF Value™: $201.38 vs. price of $37.58 (81.3% below fair value)
No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
53GF Score
Get the complete analysis for IDYA
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDYA has been successfully added to your 
